Healthesystems is attending the New York Self-Insurers Association Annual Meeting, a forum to discuss issues relating to self-insurance.
Healthesystems is attending the Workers Compensation Research Institute Issues & Research Conference for senior-level decision makers from across the workers' compensation spectrum.
Approval Date: Dec 2025
Indicated for add-on maintenance treatment of severe asthma characterized by an eosinophilic phenotype (a type of inflammation characterized by high levels of white blood cells) in patients
Approval Date: Dec 2025
Indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in obese adults and overweight adults with at least one weight-related comorbidity. This approval is for a new oral tablet formulation of Wegovy, making it the first orally available GLP-1 medication for obesity.
Approval Date: Dec 2025
Indicated for the treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis
Approval Date: Dec 2025
A biosimilar to Prolia® (denosumab), this drug is a RANKL inhibitor indicated for the treatment of osteoporosis in postmenopausal women with high risk of fracture, to increase bone mass in men with osteoporosis at a high risk for fracture, for the treatment of glucocorticoid-induced osteoporosis in men and women with high risk of fracture, and more
Approval Date: Dec 2025
Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, this approval is for a first-time generic
Approval Date: Nov 2025
Indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern. This approval is for a first-time generic
Approval Date: Oct 2025
Indicated for the treatment of hypertension to lower blood pressure, a new oral solution formulation of this drug is now available
Approval Date: Sep 2025
A lidocaine and amide local anesthetic patch indicated for the relief of pain associated with post-herpetic neuralgia (shingles pain)
Approval Date: Sep 2025
A biosimilar to Prolia®, this drug is a RANKL inhibitor indicated for the treatment of osteoporosis in postmenopausal women with high risk of fracture, to increase bone mass in men with osteoporosis at a high risk for fracture, for the treatment of glucocorticoid-induced osteoporosis in men and women with high risk of fracture, and more
Approval Date: Sep 2025
A new oral suspension formulation of lamotrigine, this drug is indicated for the treatment of partial-onset seizures and bipolar disorder
Approval Date: Aug 2025
A GLP-1 receptor antagonist, this drug is indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity, or who are overweight with at least one weight-related comorbidity. This is the first generically available GLP-1 receptor agonist for the treatment of obesity.
Approval Date: Jul 2025
A muscle relaxant indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions
Approval Date: Jul 2025
An NSAID indicated for the treatment of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis
Approval Date: Jul 2025
Indicated alone or in combination with other antihypertensive and antianginal agents for the treatment of hypertension or coronary artery disease
Approval Date: Jul 2025
Indicated for the treatment of hypertension to lower blood pressure, in patients 55 and older to reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes, and in patients with post-myocardial infarction heart failure to reduce risk of death and hospitalization
